-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Opinion - Reducing cardiovascular risk: too little, too late, too short-term
(2258) Views (407) Full article downloads
Authors: David Gray
Published Date January 2005
Volume 2005:1(1) Pages 3 - 5
DOI: http://dx.doi.org/10.2147/VHRM.S
David Gray
University Hospital, Nottingham, UK
Vascular diseases in general, and cardiovascular disease in particular, are diseases of mass destruction, killing more people in the Western world (and increasingly in the developing world) than world wars. Each year, coronary heart disease kills over half a million Americans and over 100 000 British citizens each year, often prematurely (WHO online).
Readers of this article also read:
A new paradigm of cardiovascular risk factor modification
Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Erratum
A case of recurrent bloody tears
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
